CENTOGENE engages in diagnosis and research around rare diseases transforming real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. Its goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using its extensive rare disease knowledge, including epidemiological and clinical data, as well as innovative biomarkers. CENTOGENE has developed a global proprietary rare disease platform based on its real-world data repository with over 3.6 billion weighted data points from approximately 595,000 patients representing over 120 different countries as of September 30, 2020. The Company's platform includes epidemiologic, phenotypic, and genetic data that reflects a global population, and also a biobank of these patients' blood samples. CENTOGENE believes this represents the only platform that comprehensively analyzes multi-level data to improve the understanding of rare hereditary diseases, which can aid in the identification of patients and improve its pharmaceutical partners' ability to bring orphan drugs to the market. As of September 30, 2020, the Company collaborated with over 40 pharmaceutical partners covering over 45 different rare diseases.

Company profile
Ticker
CNTG
Exchange
Website
CEO
Arndt Rolfs
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Centogene B.V.
SEC CIK
CNTG stock data
News

Stocks That Hit 52-Week Lows On Monday
13 Jun 22
CENTOGENE and Agios Expand Partnership For Clinical Development Of PYRUKYND To Treat Children With Rare Blood Disease
13 Jun 22
Stocks That Hit 52-Week Lows On Friday
3 Jun 22
Stocks That Hit 52-Week Lows On Thursday
2 Jun 22
Stocks That Hit 52-Week Lows On Thursday
26 May 22
Press releases
CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND® (mitapivat) to Treat Children With Rare Blood Disease
13 Jun 22
CENTOGENE's CentoCloud® Is Now CE-Marked as One of the Only Decentralized SaaS Platforms Compliant With European IVD Regulatory Framework
25 May 22
CENTOGENE Contributes to Europe-Wide Efforts to Update Guidelines for Whole Genome Sequencing (WGS) in Rare Disease Diagnostics
23 May 22
CENTOGENE to Present at the H.C. Wainwright Global Investment Conference
19 May 22
CENTOGENE and Takeda Extend Market Access and Expansion Partnership to Advance Patient Care Globally
28 Apr 22
Calendar
31 Mar 22
26 Jun 22
31 Dec 22
Financial summary
Quarter (USD) | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Institutional ownership, Q4 2021
38.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 10 |
Opened positions | 0 |
Closed positions | 9 |
Increased positions | 3 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 69.93M |
Total shares | 8.49M |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
DPE Deutsche Private Equity Gesellschaft mbH | 6.04M | $57.1M |
Platinum Investment Management | 2.28M | $11.91M |
Acadian Asset Management | 70.73K | $366K |
Renaissance Technologies | 48.47K | $253K |
BLK Blackrock | 21.42K | $111K |
NTRS Northern Trust | 13.45K | $70K |
Geode Capital Management | 11.16K | $57K |
JPM JPMorgan Chase & Co. | 7.29K | $37K |
Meeder Asset Management | 5.17K | $27K |
BAC Bank Of America | 309 | $1K |
Financial report summary
?Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
Current reports
6-K
CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND® (mitapivat) to Treat Children With Rare Blood Disease
13 Jun 22
6-K
Current report (foreign)
7 Jun 22
6-K
CENTOGENE’s CentoCloud® Is Now CE-Marked as One of the Only Decentralized SaaS Platforms Compliant With European IVD Regulatory Framework
25 May 22
6-K
CENTOGENE Contributes to Europe-Wide Efforts to Update Guidelines for Whole Genome Sequencing (WGS) in Rare Disease Diagnostics
23 May 22
6-K
CENTOGENE to Present at the H.C. Wainwright Global Investment Conference
19 May 22
6-K
CENTOGENE Announces Departure From Executive Team
3 May 22
6-K
CENTOGENE and Takeda Extend Market Access and Expansion Partnership to Advance Patient Care Globally
28 Apr 22
6-K
CENTOGENE Reports Fourth Quarter and Fiscal Year 2021 Financial Results
30 Mar 22
6-K
CENTOGENE CEO Kim Stratton to Speak at BIO-Europe Spring® 2022 Conference
24 Mar 22
6-K
Current report (foreign)
23 Mar 22
Registration and prospectus
424B4
Prospectus supplement with pricing info
10 Jul 20
F-1
Registration statement (foreign)
7 Jul 20
DRS
Draft registration statement
25 Jun 20
DRSLTR
Correspondence regarding draft registration statement
25 Jun 20
424B4
Prospectus supplement with pricing info
8 Nov 19
S-8
Registration of securities for employees
7 Nov 19
8-A12B
Registration of securities on exchange
4 Nov 19
F-1/A
Registration statement (foreign) (amended)
28 Oct 19
F-1
Registration statement (foreign)
11 Oct 19
DRS/A
Draft registration statement (amended)
27 Mar 19
Proxies
No filings
Other
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
31 Mar 22
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
15 Apr 21
EFFECT
Notice of effectiveness
10 Jul 20
CORRESP
Correspondence with SEC
6 Jul 20
CORRESP
Correspondence with SEC
6 Jul 20
UPLOAD
Letter from SEC
29 Jun 20
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
23 Apr 20
EFFECT
Notice of effectiveness
7 Nov 19
CERT
Certification of approval for exchange listing
6 Nov 19
CORRESP
Correspondence with SEC
3 Nov 19
Ownership
SC 13D/A
Centogene / TVM Life Science Innovation I ownership change
11 Mar 22
SC 13D/A
Centogene / DPE Deutsche Private Equity Gesellschaft mbH ownership change
22 Feb 22
SC 13G
Centogene / PLATINUM INVESTMENT MANAGEMENT ownership change
8 Dec 21
144
Notice of proposed sale of securities
12 Jul 21
144
Notice of proposed sale of securities
7 Jul 21
SC 13D/A
Centogene / DPE Deutsche Private Equity Gesellschaft mbH ownership change
12 May 21
SC 13G/A
Centogene / Rolfs Arndt ownership change
16 Feb 21
144
Notice of proposed sale of securities
27 Jan 21
SC 13D/A
Centogene / DPE Deutsche Private Equity Gesellschaft mbH ownership change
5 Nov 20
SC 13D/A
Centogene / TVM Life Science Innovation I ownership change
3 Nov 20
Patents
Utility
Method for the Diagnosis of Metachromatic Leukodystrophy
9 Sep 20
The present invention is related to a method for diagnosing metachromatic leukodystrophy in a subject comprising a step a), wherein the step a) comprises detecting a biomarker in a sample from the subject, wherein the sample is selected from the group consisting of blood, dried blood, serum and plasma and wherein the biomarker is different from an enzyme.
Utility
Method for the diagnosis of metachromatic leukodystrophy
22 Jun 20
The present invention is related to a method for diagnosing metachromatic leukodystrophy in a subject comprising a step a), wherein the step a) comprises detecting a biomarker in a sample from the subject, wherein the sample is selected from the group consisting of blood, dried blood, serum and plasma and wherein the biomarker is different from an enzyme.
Utility
Method for the Diagnosis of Niemann-Pick Disease
4 Mar 20
Inventors: Arndt Rolfs, Hermann Mascher
Reddit threads
Daily Discussion Thread - June 22nd, 2022
22 Jun 22
Daily Discussion Thread - June 21st, 2022
21 Jun 22
Daily Discussion Thread - June 15th, 2022
15 Jun 22
Daily Discussion Thread - June 14th, 2022
14 Jun 22
Pre-market summary - June 13th
13 Jun 22
Daily Discussion Thread - June 13th, 2022
13 Jun 22
Daily Discussion Thread - March 30th, 2022
30 Mar 22
Daily Discussion Thread - March 29th, 2022
29 Mar 22
Daily Discussion Thread - March 28th, 2022
28 Mar 22
Daily Discussion Thread - November 24th, 2021
24 Nov 21